Oncocyte (id:5921 OCX)

2.19 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 8:10:42 PM)

Exchange closed, opens in 13 hours 19 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• 5 years
• All

About Oncocyte

Market Capitalization 37.54M

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.